The new program provides eligible research studies with in-kind support for the use of the RESP® Biosensor system.
Philadelphia, PA, March 20, 2025 – Strados Labs, a medical technology company, is announcing the launch of a new grant initiative developed to accelerate research into the role of continuous cough and lung sound monitoring in disease surveillance. The Strados Research Grant provides in-kind support to eligible research studies for the use of RESP Biosensors and Strados Labs reporting services for the duration of the study.
While lung auscultation has been key in diagnosing and managing respiratory diseases for over a century, it has historically been limited to brief, in-person assessments using a stethoscope. As a result, clinicians have missed fluctuations that can occur outside of clinical visits. Additionally, while patient reporting of symptoms such as cough and wheeze remains highly useful in assessing respiratory status, it is also prone to recall bias and subjectivity. Wearable devices such as the RESP Biosensor represent a major shift, allowing for objective and continuous monitoring lung sounds such as cough and wheeze from hospital to home.
Increasing Our Understanding of Continuous Auscultation
By offering in-kind support for the use of the RESP Biosensor system in research studies, Strados Labs aims to advance our understanding of the value of lung sound monitoring in patient care and research. The grant is intended primarily for academic research studies conducted by universities, health systems, agencies, or independent researchers. Disease areas that may see the greatest impact from continuous lung sound monitoring include:
- Chronic respiratory diseases, such as COPD, asthma, interstitial lung diseases, and bronchiectasis
- Infectious diseases such as RSV, influenza, and COVID
- Lung cancers including non-small cell lung cancer
- Cardio-pulmonary interactions including congestive heart failure and pulmonary edema
“The research on continuously monitoring lung sounds is still in its early stages, largely because it simply wasn’t possible until recent years,” said Nick Delmonico, CEO & Cofounder of Strados Labs. “With the Strados Research Grant, we hope to accelerate research in this space; by doing so, we believe this will lead to new discoveries that could result in better patient outcomes in the future.
Applications Now Open
The Strados Research Grant is now accepting applications. Researchers interested in including continuous lung sound monitoring in their studies are encouraged to apply.
For any questions about the grant, contact research@stradoslabs.com.
About Strados Labs
Strados Labs is a medical technology company focused on improving the lives of patients with respiratory diseases. Enabling remote monitoring of lung health, Strados Labs’ RESP Biosensor allows clinicians to continuously measure patients’ lung sounds such as cough and wheeze that can indicate an exacerbation or reduced quality of life. The technology is used to assist drug developers in demonstrating treatment efficacy in clinical trials and to support clinicians in patient disease surveillance and management. The RESP Biosensor is FDA-cleared, CE marked and HIPAA compliant, backed by multiple awards and clinical publications. Strados Labs is privately owned and based in Philadelphia, PA.
For more information, visit Stradoslabs.com or follow us on LinkedIn and X.
Media Contact:
Gabe Steerman
gabe@stradoslabs.com
stradoslabs.com